Vimarsana
Biggest News Aggregation in the World

Page 3 - Bymark Leiser News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bymark Leiser. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bymark Leiser Today - Breaking & Trending Today

Biomarkers predict benefit of adjuvant nivolumab in resected melanoma - Vimarsana News

Biomarkers predict benefit of adjuvant nivolumab in resected melanoma

CHICAGO — Several biomarkers predicted outcomes with adjuvant nivolumab vs. placebo for patients with resected stage IIB or IIC melanoma, according to study results presented at ASCO Annual Meeting.In contrast to prior findings in melanoma, no biomarkers appeared prognostic for RFS among patients who received placebo.

Source: healio.com
NCI director: 'Committed and collective action' required to achieve Moonshot goal - Vimarsana News

NCI director: 'Committed and collective action' required to achieve Moonshot goal

CHICAGO — “Committed and collective action” will be required if a key goal of the Cancer Moonshot — reducing cancer mortality by at least 50% in 25 years — will be met, the NCI director told ASCO Annual Meeting attendees.“We won’t succeed if we stay in our silos, and we won’t succeed by pointing fingers,” Monica M. Bertagnolli, MD, FACS,

Source: healio.com
Late-toxicity burden high among survivors of high-risk neuroblastoma - Vimarsana News

Late-toxicity burden high among survivors of high-risk neuroblastoma

CHICAGO — Survivors of high-risk neuroblastoma face a substantial burden of late toxicity, according to study results presented at ASCO Annual Meeting.Prevalence of some late effects vary by treatment received, findings showed.

Source: healio.com
Zanidatamab induces response in refractory HER2-positive biliary tract cancer - Vimarsana News

Zanidatamab induces response in refractory HER2-positive biliary tract cancer

CHICAGO — Zanidatamab induced durable responses among patients with previously treated HER2-amplified biliary tract cancer, according to study results presented at ASCO Annual Meeting.The agent also exhibited a manageable safety profile, investigators who conducted the phase 2b HERIZON-BTC-01 study concluded.

Source: healio.com
Pembrolizumab improves outcomes in early-stage resectable lung cancer - Vimarsana News

Pembrolizumab improves outcomes in early-stage resectable lung cancer

CHICAGO — The addition of pembrolizumab to neoadjuvant chemotherapy followed by adjuvant pembrolizumab improved outcomes for patients with early-stage resectable non-small cell lung cancer, according to findings presented at ASCO Annual Meeting.Results of the randomized phase 3 KEYNOTE-671 trial — published simultaneously in The New England Journal of Medicine — showed a

Source: healio.com